- Registration Date 2016-10-14
- Hit 3264
Company Information |
|
1. Name |
Samsung Bioepis |
2. Website Address |
www.samsungbioepis.com |
3. Location |
Songdo Site : 107, Cheomdan-daero, Yeonsu-gu, Incheon, 21987 Republic of Korea |
4. Contacts |
General : episinfo@samsung.com Media : bioepispr@samsung.com |
5. References |
|
Pharmaceutical Product Information |
|
1. Brand Name |
BRENZYS® |
2. Active Ingredient |
Etanercept |
3. Indication |
[Korea]
Rheumatoid arthritis, Psoriatic arthritis, Axial spondyloarthritis (Ankylosing spondylitis and non-radiographic axial spondyloarthritis), Plaque psoriasis |
4. Information |
Following an approval in Sep 2015 in Korea, it was approved in EU (Jan 2016), Australia (Jul 2016) and Canada (Aug 2016) BRENZYS® is a fusion protein which inhibits turnor necrosis factor alpha, known to modulate immune responses. * BRENZYS® is commerciallized in EU as BENEPALI®. |
Pharmaceutical Product Information |
|
1. Brand Name |
RENFLEXIS® |
2. Active Ingredient |
Infliximab |
3. Indication |
[Korea] Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Psoriasis, Crohn's disease, Ulcerative colitis |
4. Information |
Following an approval in Dec 2015 in Korea, it was approved in EU (May 2016). RENFLEXIS® is a monoclonal antibody(mAb) which inhibits turnor necrosis factor alpha, known to modulate immune responses. * RENFLEXIS® is commerciallized in EU as FLIXABI®. |
Division
Written by 전형옥